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to one more relapse among many before being diverted to known lithium or some other drug (preserving the trial code intact). The fact that others have terminated studies prematurely (Laurel and Ottosson, 1968) is at least as much due to precon ceived notions and public hysteria as to data arising from the abandoned trial. Nor is the lack ofa suitable control drug a worthy objection. Schou himself originally claimed that imipramine might have similar prophylactic effects (Schou, :963) , and Melia has now shown that placebo can be effective for long periods (Melia, 1970) The contention that studies on chronic depression are not subject to placebo effects or observer bias to placebos or drugs in depression (Honigfeld, 1963) . A recent collaborative study involving 555 depressed in-patients showed that placebo produces quite marked benefits on a number of symptoms and subtypes of depression. Furthermore, drug treatment differences accounted for only 10 per cent of the variance in outcome (Raskin, Schulterbrandt, Reatig, and McKeon, :970) . The view that chronic refractory illnesses treated by enthusiasts are not amenable to non-drug influences is barely credible if one considers that it is precisely such situations which compose the â€˜¿ panacea paradigm' (Blackwell, 1969) .In a recentreview on the placeboeffect, Shapiro (1970) has described a phenomenon called â€˜¿ indirect iatroplacebogenesis' where placebo effects are â€˜¿ produced or augmented when the physician is prestigous, dedicated to his theory and therapy, especially if it is his own innovation, or if he is a recent convert, or when the therapies are elaborate, detailed, expensive, time consuming, fashionable, esoteric, or dangerous.' Recent research has suggested that the placebo response in double-blind studies may vary from 24 to 76 per cent under the influence of such variables (Lowinger and Dobie, :@6g Its potential influence on the patient is even more profound and appears to be supported by the data (Table III) . Putting aside those patients who re inained well for the entire period of 730 days and the patient with toxicity, there is a marked difference in the relapse behaviour in the two treatment groups.
Five of the six placebo patients fell ill within three months (92 days). At first sight, this appears to confirm the experimental hypothesis; but a corn parison of the pre-and post-trial behaviour of the two groups suggests otherwise. The lithium group had a pre-treatment frequency of 3 . 14 episodes a year, amounting to an episode each : : 6 days (Table II) . On lithium, they remained in remission for a mean of : I i days (234, 109, 66, and 35 days).
The placebo group had a pre-treatment episode frequency of 2 @ 50 episodes a year or an episode each 146 days. After initiation of placebo they had a mean relapse rate of 76 days (269, 92, 57, 48, 32, 27 and 8 days). These calculations suggest that the patients placed on lithium remained unchanged and unimproved, whilst those on placebo deteriorated.
Dr. Melia's study, therefore, appears to support the following conclusions:
I . Both lithium and placebo may produce pro longed remission in a few instances.
Lithium occasionally causes serious toxicity.
3. Other patients do not improve on lithium, but may be made worse if switched to placebo. This ispossibly becausethey detectthe subterfuge because of the appearance of withdrawal effects or disappearance of side effects.
The last conclusion invokes psychological as well as physiological mechanisms and is difficult to test, but it may be supported by observing that the patients who were selected for this study were those whose attendance and compliance was most faithful, and who might be most attuned to detect change, and consequently most affected by it. At least one physio logical mechanism that might account for the patients' 
